![](https://www.innovations-report.com/wp-content/uploads/2013/06/crop-in-fields-300x200.jpg)
Improved CAR T-cells – Bispecific chimeric antigen receptors with a CD30 binding domain
![](https://www.innovations-report.com/wp-content/themes/innovation-report-2/assets/dist/img/placeholder-single-thumbnail.png)
Adoptive T-cell therapy is a very promising approach in the treatment of cancer. Early phase clinical trials with genetically engineered T-cells expressing a tumor-specific chimeric antigen receptor (CAR) show significant efficacy in the treatment. However, currently used CAR modified T-cells for antigen-directed targeting towards tumor cells have insufficient performance in the anti-tumor attack, e. g. less amplification and cytolytic activity after the transfer of the modified T-cells into the patient. Scientists from the University Medical Center of Cologne developed a bispecific CAR, which improves the performance of genetically engineered T-cells expressing these CAR polypeptides on their surface. The bispecific CAR comprises two antibody units, with one antibody unit being an anti-CD30 single chain antibody unit and the other antibody unit being an antibody unit specific for an antigen present on the surface of a predetermined target cell, e. g. for the tumor carcino-embryonic antigen (CEA) on breast cancer cells.
Further information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.